Currently identified driver genetic abnormalities and signaling pathways of advanced bladder cancer include mutations in TERT gene promoter, FGFR3 mutations, and ERBB2 and ERBB3 mutations. The gene discussed is FGFR3; the disease is urinary bladder cancer.